Nestlé acquires CM&D Pharma

Nestlé Health Science has acquired CM&D Pharma, a small UK company specialising in the research and development, marketing and sales of foods for specialist medical purposes. The company's portfolio comprises products tailored for patients with kidney disease, inflammatory bowel disease and colon cancer.

The financial details of the acquisition, which took place just one month after Nestle Health Science became operational, have not been disclosed. Nestlé Health Science is a fully-owned subsidiary of Nestlé SA and will develop science-based nutritional solutions to deliver personalised healthcare for medical conditions.

CM&D's leading product is Fostrap, a medical chewing gum for kidney patients with hyperphosphataemia (an elevated level of phosphate in the blood). Its other products include Reclonix for the treatment of abdominal pain often associated with Crohn's Disease; ulcerative colitis; or non-specific inflammatory bowel disease and Eviendep, a unique colon protector is intended to slow down the progression of polyps to colon cancer and to prevent their reoccurrence following removal.

CM&D founder, Danilo Casadei Massari, commented: "The Board of CM&D Pharma is confident that now, with a trade shareholder with unparallelled expertise and understanding of the science and the regulatory environment behind dietary management of health conditions, its product portfolio will be fully exploited.  We are also pleased to have maintained our promise to our original shareholders, and rewarded them for their faith in us."